AbbVie Inc. (BMV:ABBV)
Mexico · Delayed Price · Currency is MXN | Market Cap | 9.80T +33.9% |
| Revenue (ttm) | 1.19T +10.7% |
| Net Income | 185.69B +333.1% |
| EPS | 109.11 +339.8% |
| Shares Out | n/a |
| PE Ratio | 50.82 |
| Forward PE | 19.18 |
| Dividend | 126.16 (2.28%) |
| Ex-Dividend Date | Jan 15, 2027 |
| Volume | 58 |
| Open | 5,582.00 |
| Previous Close | 5,460.00 |
| Day's Range | 5,544.00 - 5,582.00 |
| 52-Week Range | 3,420.00 - 5,545.00 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie Science Chief says interested in building out obesity assets
AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that…
AbbVie says too early to determine financial impact from 340B rebate pilot
10:00 EDT AbbVie (ABBV) says too early to determine financial impact from 340B rebate pilot
AbbVie sees Q4 adjusted EPS $3.83-$3.87, consensus $3.89
Sees Q4 revenue about $18.4B, consensus $18.3B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
09:35 EDT AbbVie (ABBV) sees FY26 adjusted gross margin ‘above 84% of sales’
AbbVie sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B
09:40 EDT AbbVie (ABBV) sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B
AbbVie says making ‘significant progress’ advancing pipeline
Says delivering “strong execution” across the business. Says Skyrizi, Rinvoq “exceeding expectations.” Comments taken from Q3 earnings conference call.
AbbVie sees FY26 revenue about $67.8B, consensus $67.62B
Prior view was FY26 revenue about $67.6B.
AbbVie Earnings Call Transcript: Q3 2026
Q3 revenue rose 10.5% operationally and adjusted EPS beat the midpoint, prompting higher FY guidance. Immunology and neuroscience led growth as pipeline milestones broadened longer-term prospects.
AbbVie Earnings release: Q3 2026
AbbVie released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
The pharmaceutical company boosted its profit outlook for the year, and raised its quarterly dividend as both third-quarter results and full-year guidance came in above expectations.
AbbVie reports Q3 adjusted EPS $3.82, consensus $3.77
Reports Q3 revenue $17.4B, consensus $17.34B. “AbbVie (ABBV) continues to deliver outstanding results, reflecting solid execution across our diverse portfolio,” said Robert Michael, chairman and chief...
AbbVie raises FY26 adjusted EPS view to $13.95-$13.99 from $13.76-$13.96
FY26 consensus $13.95. The company’s 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both…
AbbVie raises quarterly dividend 5.2% to $1.82 from $1.73 per share
AbbVie (ABBV) is announcing that its board of directors declared an increase in the company’s quarterly cash dividend from $1.73 per share to $1.82 per share beginning with the dividend…
AbbVie Reports Third-Quarter 2026 Financial Results
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Im...
AbbVie reports TEMPLE study meets primary endpoint, publishes results
AbbVie (ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head study evaluated the tolerability, safety and effica...
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks th...
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alon...
AbbVie submits BLA for etentamig to U.S. FDA
AbbVie (ABBV) announced the submission of a Biologics License Application to the U.S. FDA for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager administered intravenously fo...
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings...
Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.
Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide. A STEM-focused workshop in San Antonio will b...
A Worthwhile Exit Strategy
This week could mark something that hasn't happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It's all going to depend on if the share price end...
FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s
AbbVie (ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous induction regimen for Skyrizi for adults with moderately to severely active Crohn’s disease. “Patients now hav...
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the...
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after AbbVie’s (ABBV) Phase 3 INTREPID study ...
AbbVie price target raised to $294 from $258 at Goldman Sachs
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVies lutikizumab met Phase 3 endpoints in hidradenitis…